Showing 1 - 20 results of 239 for search '(( 100 mg decrease ) OR ((((( _ best decrease ) OR ( _ el decrease ))) OR ( 50 a decrease ))))*', query time: 0.14s Refine Results
  1. 1
  2. 2

    Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…<p dir="ltr">Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex: Frontiers in Molecular Biosciences <a href="https://dx.doi.org/10.3389/fmolb.2022.846996" target="_blank">https://dx.doi.org/10.3389/fmolb.2022.846996</a>, published online 22 July 2022.…”
  3. 3

    Ecotoxicological Assessment of Thermally- and Hydrogen-Reduced Graphene Oxide/TiO<sub>2</sub> Photocatalytic Nanocomposites Using the Zebrafish Embryo Model by Halema Al-Kandari (6316961)

    Published 2019
    “…H<sub>2</sub>RGOTi showed a NOEC similar to RGOTi. However, no significant mortality was detected at all concentrations used in the acutoxicity assay (up to1000 mg/L), thus indicating a hypothetical LC<sub>50</sub> higher than 1000 mg/L. …”
  4. 4
  5. 5
  6. 6

    Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study by Brit Mollenhauer (482499)

    Published 2018
    “…<p dir="ltr">α‐Synuclein is the major component of Lewy bodies and a candidate biomarker for neurodegenerative diseases in which Lewy bodies are common, including Parkinson's disease and dementia with Lewy bodies. …”
  7. 7
  8. 8

    Novel thiazolones for the simultaneous modulation of PPARγ, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation by Mai S., El-Shoukrofy

    Published 2025
    “…Compound 2a activated PPARγ with an EC50 value of 3.4 μM in a Gal4-hybrid reporter gene assay, indicating partial agonistic action. …”
    Get full text
    Get full text
    Get full text
    article
  9. 9
  10. 10

    Novel thiazolones for the simultaneous modulation of PPARγ, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation by Mai S. El-Shoukrofy (19646815)

    Published 2025
    “…Compound 2a activated PPARγ with an EC<sub>50</sub> value of 3.4 μM in a Gal4-hybrid reporter gene assay, indicating partial agonistic action. …”
  11. 11
  12. 12

    A Power Ripple Compensator for DC Nanogrids via a Solid-State Converter by Ahmad Khan (6067526)

    Published 2020
    “…<h3>Abstract</h3><p dir="ltr">This paper presents a method for improving the reliability of DC nanogrids by decreasing the input capacitance requirement. …”
  13. 13
  14. 14
  15. 15

    Appropriateness of gentamicin therapeutic drug monitoring at a Middle Eastern tertiary hospital setting: a retrospective evaluation and quality audit by Fatima Khalifa Al-Sulaiti (14152056)

    Published 2024
    “…<h3>Introduction</h3><p dir="ltr">The use of gentamicin in the treatment of infectious diseases requires frequent monitoring to attain the best treatment outcomes.</p><h3>Objective</h3><p dir="ltr">This study aimed to evaluate the appropriateness of gentamicin therapeutic drug monitoring (TDM) at a tertiary care hospital in Qatar.…”
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Chromogranin A‐positive hormone‐negative endocrine cells in pancreas in human pregnancy by Abu Saleh Md Moin (6189512)

    Published 2023
    “…However, an increase in the percentage of clustered β-cells was found in pregnancy, with decreased frequency of other endocrine cells in clusters, suggesting a compensatory shift from other pancreatic endocrine cell types to β-cells as a mechanism to meet the increased insulin demands of pregnancy.…”